Activities of loracarbef, against the species of bacteria commonly causing communityacquired respiratory, skin and urinary tract infections, were determined by the agar dilution test. However, the strains used were mostly isolated from
inpatients,
not
from outpatients. MIC ranges (in㎍/ml) of loracarbef were:≤0.12 against S. pyogenes, 1-2 against S. agalactiae, 1-4 against penicillin G (PEN)-susceptible S. aureus, 1-8 against PEN-resistant S. aureus, ≤0.12 against PEN-susceptible
coagulase-negative
staphylococci (CNS) and 0.5-8 against PEN-resistant CNS, 0.5-8against M.(B.) catarrhalis, 2-16 againstβ-lactamase (BL)-positive H. influenzae, 0.5-8 against BL-negative H. influenzae, 0.25-2 against E. coli and P. mirabilis and o.5-64 against K.
pneumoniae. Except 5% of K. pneumoniae, all the other strains were interpreted to be susceptible to loracarbef. The resistance rates to amoxicillin were: 100% of PEN-resistant staphylococci, 95% of M. (B.) catarrhalis, all of BL-positive H.
influenzae
and K. pneumoniae, 90% of E. coli and 32% of P. mirabilis. It is concluded that the in vitro susceptibility indicates the usefulness of loracarbef for the treatment of most of the community-acquired respiratory, skin and urinary tract infections.
|